Generics

Intas B2B portfolio is constantly growing across multiple therapeutic areas, specialized in CNS and Cardiovascular. Intas is also vertically integrated into some APIs (Active Pharmaceutical Ingredients)

Generics

To view our Genereics specific dossier portfolio, Please visit our app.
001_icon_aAlimentary tract & Metabolism
001_icon_bAntiinfectives
001_icon_cCardiovascular System
001_icon_dDermatology
001_icon_eGenito-urinary System
Hematology
Hormonal System
Immunosuppression & Autoimmune Diseases
Musculo-skeletal System
001_icon_gNervous System
Oncology
Ophtalmology
001_icon_fRespiratory System
Generics
To view our Generics specific dossier portfolio, Please visit our app.
Please click here

DAY ONE LAUNCHES

Australian Market

Lacosamide was launched in Australia in March 2022. 

Canadian Market

Dimethyl Fumarate was launched in Canada in October 2021

LATAM Market

Rivaroxaban was launched in Chile in October 2021

European Market

Amlodipine + Olmesartan +
Hydrochlorothiazide was launched in Europe in December 2020

Australian Market

Solifenacin film-coated tablets and orally disintegrated tablets was launched in Australia in December 2020.

Tadalafil was launched in Australia in August 2020

Intas Intellectual Property department is one of the most important pillars for achieving ‘day one launches’, which ensures high-quality medicines are more accessible.

None of the products listed above are available for countries where the offer and/or supply of the product could be deemed an infringement of the intellectual property rights of third parties.